Meeting
2019 Genitourinary Cancers Symposium
Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Marcus Marie Moses
Tulane University, New Orleans, LA
Marcus Marie Moses , Elisa Ledet , Charlotte Manogue , Brian E. Lewis , Pedro C. Barata , A. Oliver Sartor , Jodi Lyn Layton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 255)
DOI
10.1200/JCO.2019.37.7_suppl.255
Abstract #
255
Poster Bd #
L12
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christophe Massard
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
First Author: Christophe Massard
Poster
2019 Genitourinary Cancers Symposium
Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
First Author: Peter C.C. Fong